Search Results for "fenofibrate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fenofibrate. Results 1 to 6 of 6 total matches.
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
once/day or divided26 421.2023
5 g/scoop
Fibric Acid Derivatives
Fenofibrate – generic 54, 160 mg ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Elafibranor (Iqirvo) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
to UDCA monotherapy; addition
of fenofibrate was associated with improved rates of
decompensation-free ...
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated
receptor (PPAR) agonist, has been granted
accelerated approval by the FDA for treatment of
primary biliary cholangitis (PBC) in adults. It is
indicated for use in combination with ursodeoxycholic
acid (ursodiol, UDCA; Urso, and others) in patients
with an inadequate response to UDCA alone and as
monotherapy in those unable to tolerate UDCA.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-4 doi:10.58347/tml.2024.1718b | Show Introduction Hide Introduction
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
Derivatives
Fenofibrate – generic
Fenoglide16 (Santarus)
Lipofen16 (Kowa)
54, 160 mg tabs
40, 120 mg tabs ...
View the Comparison Table: Some Lipid-Lowering Drugs
Seladelpar (Livdelzi) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
of fenofibrate was associated with improved rates of
decompensation-free and transplant-free survival in
one ...
Seladelpar (Livdelzi – Gilead), a peroxisome
proliferator-activated receptor (PPAR)-delta agonist,
has received accelerated approval from the FDA for use
in combination with ursodeoxycholic acid (ursodiol,
UDCA; Urso Forte, and generics) for treatment of
primary biliary cholangitis (PBC) in adults who had an
inadequate response to UDCA and as monotherapy in
those unable to tolerate UDCA. Accelerated approval
was based on a reduction in alkaline phosphatase
(ALP) levels. Seladelpar is the second PPAR agonist
to be approved in the US for this indication; elafibranor
(Iqirvo)...
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-5 doi:10.58347/tml.2025.1720d | Show Introduction Hide Introduction
Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
)
amiodarone
capecitabine
ceritinib
delavirdine
efavirenz
etravirine
fenofibrate
floxuridine ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30 doi:10.58347/tml.2023.1669g | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
fenofibrate have
uricosuric effects.33 They may be beneficial for
adjunctive prevention of gout flares ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction